Cargando…

Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of ldl subfraction phenotype

BACKGROUND: Type 2 diabetes mellitus (T2D) is associated with higher cardiovascular risk partly related to an increase in inflammatory parameters. The aim of this study was to determine the association of inflammatory biomarkers with low-density lipoprotein (LDL) subfraction phenotype and glycemic c...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinagre, Irene, Sánchez-Quesada, José Luis, Sánchez-Hernández, Juan, Santos, David, Ordoñez-Llanos, Jordi, De Leiva, Alberto, Pérez, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922962/
https://www.ncbi.nlm.nih.gov/pubmed/24495560
http://dx.doi.org/10.1186/1475-2840-13-34
_version_ 1782303539642499072
author Vinagre, Irene
Sánchez-Quesada, José Luis
Sánchez-Hernández, Juan
Santos, David
Ordoñez-Llanos, Jordi
De Leiva, Alberto
Pérez, Antonio
author_facet Vinagre, Irene
Sánchez-Quesada, José Luis
Sánchez-Hernández, Juan
Santos, David
Ordoñez-Llanos, Jordi
De Leiva, Alberto
Pérez, Antonio
author_sort Vinagre, Irene
collection PubMed
description BACKGROUND: Type 2 diabetes mellitus (T2D) is associated with higher cardiovascular risk partly related to an increase in inflammatory parameters. The aim of this study was to determine the association of inflammatory biomarkers with low-density lipoprotein (LDL) subfraction phenotype and glycemic control in subjects with T2D and poor glycemic control. METHODS: A cross-sectional study was performed comparing 122 subjects with T2D (59 ± 11 years old, body mass index 30.2 ± 5.6 kg/m2) with 54 control subjects. Patients with T2D were classified according to their LDL subfraction phenotype and inflammatory biomarkers (C-reactive protein, Interleukin-6, Interleukin-8, Transforming growth factor β(1), Monocyte chemotactic protein 1, Leptin, Adiponectin) were evaluated according to the degree of glycemic control, LDL phenotype and other clinical characteristics. Forty-two subjects with T2D were studied before and after 3 months of improving glycemic control by different strategies. RESULTS: Patients with T2D had higher C-reactive protein (CRP) and monocyte chemotactic protein-1 (MCP1) levels and lower adiponectin concentration, compared to controls. T2D subjects with body mass index ≥ 30 kg/m2 had higher CRP levels (5.2 ± 4.8 mg/l vs 3.7 ± 4.3 mg/l; p < 0.05). The presence of LDL phenotype B was related to higher levels of transforming growth factor-β(1) (TGF-β(1)) (53.92 ± 52.82 ng/l vs 31.35 ± 33.74 ng/l; p < 0.05) and lower levels of adiponectin (3663 ± 3044 ng/l vs 2723 ± 1776 ng/l; p < 0.05). The reduction of HbA1c from 9.5 ± 1.8% at baseline to 7.4 ± 0.8% was associated with a significant reduction of TGF-β(1) (41.86 ± 32.84 ng/l vs 26.64 ± 26.91 ng/l; p = 0.02). CONCLUSIONS: Subjects with T2D, especially those with LDL phenotype B and obesity, have higher levels of inflammatory biomarkers. Improvement of glycemic control reduces TGF-β(1) levels, which may contribute partly to its renoprotective role.
format Online
Article
Text
id pubmed-3922962
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39229622014-05-10 Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of ldl subfraction phenotype Vinagre, Irene Sánchez-Quesada, José Luis Sánchez-Hernández, Juan Santos, David Ordoñez-Llanos, Jordi De Leiva, Alberto Pérez, Antonio Cardiovasc Diabetol Original Investigation BACKGROUND: Type 2 diabetes mellitus (T2D) is associated with higher cardiovascular risk partly related to an increase in inflammatory parameters. The aim of this study was to determine the association of inflammatory biomarkers with low-density lipoprotein (LDL) subfraction phenotype and glycemic control in subjects with T2D and poor glycemic control. METHODS: A cross-sectional study was performed comparing 122 subjects with T2D (59 ± 11 years old, body mass index 30.2 ± 5.6 kg/m2) with 54 control subjects. Patients with T2D were classified according to their LDL subfraction phenotype and inflammatory biomarkers (C-reactive protein, Interleukin-6, Interleukin-8, Transforming growth factor β(1), Monocyte chemotactic protein 1, Leptin, Adiponectin) were evaluated according to the degree of glycemic control, LDL phenotype and other clinical characteristics. Forty-two subjects with T2D were studied before and after 3 months of improving glycemic control by different strategies. RESULTS: Patients with T2D had higher C-reactive protein (CRP) and monocyte chemotactic protein-1 (MCP1) levels and lower adiponectin concentration, compared to controls. T2D subjects with body mass index ≥ 30 kg/m2 had higher CRP levels (5.2 ± 4.8 mg/l vs 3.7 ± 4.3 mg/l; p < 0.05). The presence of LDL phenotype B was related to higher levels of transforming growth factor-β(1) (TGF-β(1)) (53.92 ± 52.82 ng/l vs 31.35 ± 33.74 ng/l; p < 0.05) and lower levels of adiponectin (3663 ± 3044 ng/l vs 2723 ± 1776 ng/l; p < 0.05). The reduction of HbA1c from 9.5 ± 1.8% at baseline to 7.4 ± 0.8% was associated with a significant reduction of TGF-β(1) (41.86 ± 32.84 ng/l vs 26.64 ± 26.91 ng/l; p = 0.02). CONCLUSIONS: Subjects with T2D, especially those with LDL phenotype B and obesity, have higher levels of inflammatory biomarkers. Improvement of glycemic control reduces TGF-β(1) levels, which may contribute partly to its renoprotective role. BioMed Central 2014-02-04 /pmc/articles/PMC3922962/ /pubmed/24495560 http://dx.doi.org/10.1186/1475-2840-13-34 Text en Copyright © 2014 Vinagre et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Vinagre, Irene
Sánchez-Quesada, José Luis
Sánchez-Hernández, Juan
Santos, David
Ordoñez-Llanos, Jordi
De Leiva, Alberto
Pérez, Antonio
Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of ldl subfraction phenotype
title Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of ldl subfraction phenotype
title_full Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of ldl subfraction phenotype
title_fullStr Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of ldl subfraction phenotype
title_full_unstemmed Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of ldl subfraction phenotype
title_short Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of ldl subfraction phenotype
title_sort inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of ldl subfraction phenotype
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922962/
https://www.ncbi.nlm.nih.gov/pubmed/24495560
http://dx.doi.org/10.1186/1475-2840-13-34
work_keys_str_mv AT vinagreirene inflammatorybiomarkersintype2diabeticpatientseffectofglycemiccontrolandimpactofldlsubfractionphenotype
AT sanchezquesadajoseluis inflammatorybiomarkersintype2diabeticpatientseffectofglycemiccontrolandimpactofldlsubfractionphenotype
AT sanchezhernandezjuan inflammatorybiomarkersintype2diabeticpatientseffectofglycemiccontrolandimpactofldlsubfractionphenotype
AT santosdavid inflammatorybiomarkersintype2diabeticpatientseffectofglycemiccontrolandimpactofldlsubfractionphenotype
AT ordonezllanosjordi inflammatorybiomarkersintype2diabeticpatientseffectofglycemiccontrolandimpactofldlsubfractionphenotype
AT deleivaalberto inflammatorybiomarkersintype2diabeticpatientseffectofglycemiccontrolandimpactofldlsubfractionphenotype
AT perezantonio inflammatorybiomarkersintype2diabeticpatientseffectofglycemiccontrolandimpactofldlsubfractionphenotype